NCT03573960 2026-03-06
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
Eisai Inc.
Phase 4 Completed
Clinical Trials
6 trialsNCT01321554 2023-06-22
SELECT
Eisai Inc.
Phase 3 Completed
NCT02702388 2021-11-24
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Eisai Inc.
Phase 2 Completed
NCT01728623 2020-08-14
A Study of E7080 in Subjects With Advanced Thyroid Cancer
Eisai Inc.
Phase 2 Completed
NCT00784303 2020-04-22
Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Eisai Inc.
Phase 2 Completed
NCT02430714 2020-01-09
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Eisai Inc.
Completed